Zacks Investment Research downgraded shares of LHC Group (NASDAQ:LHCG) from a buy rating to a hold rating in a research note published on Friday, Zacks.com reports.

According to Zacks, “LHC Group, Inc. is the preferred post-acute care partner for hospitals, physicians and families nationwide. From home health and hospice care to long-term acute care and community-based services, LHC delivers high-quality, cost-effective care that empowers patients to manage their health at home. Hospitals and health systems around the country have partnered with LHC Group to deliver patient-centered care in the home. “

Several other analysts have also recently issued reports on the company. BidaskClub raised LHC Group from a hold rating to a buy rating in a research report on Tuesday, April 30th. UBS Group set a $133.00 target price on LHC Group and gave the company a buy rating in a research report on Friday, May 10th. Royal Bank of Canada increased their target price on LHC Group to $130.00 and gave the company an outperform rating in a research report on Monday, May 13th. SunTrust Banks increased their target price on LHC Group to $130.00 and gave the company a buy rating in a research report on Friday, March 1st. Finally, Robert W. Baird increased their target price on LHC Group from $98.00 to $120.00 and gave the company a neutral rating in a research report on Monday, March 4th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. LHC Group presently has an average rating of Buy and an average price target of $120.42.

Shares of NASDAQ:LHCG opened at $114.91 on Friday. LHC Group has a 52-week low of $80.84 and a 52-week high of $122.20. The company has a market capitalization of $3.62 billion, a P/E ratio of 32.37, a PEG ratio of 1.95 and a beta of 0.83. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 0.21.

LHC Group (NASDAQ:LHCG) last announced its quarterly earnings data on Wednesday, May 8th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.08. LHC Group had a return on equity of 8.43% and a net margin of 3.83%. The company had revenue of $502.59 million for the quarter, compared to analysts’ expectations of $511.16 million. As a group, equities research analysts predict that LHC Group will post 4.3 earnings per share for the current fiscal year.

In other news, Director John L. Indest sold 30,515 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $113.76, for a total value of $3,471,386.40. Following the completion of the sale, the director now owns 22,947 shares of the company’s stock, valued at approximately $2,610,450.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronald T. Nixon sold 12,000 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $117.20, for a total value of $1,406,400.00. Following the completion of the sale, the director now directly owns 29,100 shares of the company’s stock, valued at approximately $3,410,520. The disclosure for this sale can be found here. Insiders sold a total of 62,991 shares of company stock valued at $7,134,055 in the last three months. Insiders own 5.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Citigroup Inc. boosted its position in shares of LHC Group by 265.2% in the 4th quarter. Citigroup Inc. now owns 4,386 shares of the health services provider’s stock worth $412,000 after purchasing an additional 3,185 shares in the last quarter. Everence Capital Management Inc. boosted its position in shares of LHC Group by 43.6% in the 1st quarter. Everence Capital Management Inc. now owns 4,050 shares of the health services provider’s stock worth $449,000 after purchasing an additional 1,230 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its position in shares of LHC Group by 2.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 6,350 shares of the health services provider’s stock worth $704,000 after purchasing an additional 151 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of LHC Group in the 4th quarter worth $695,000. Finally, Geode Capital Management LLC boosted its position in shares of LHC Group by 6.7% in the 4th quarter. Geode Capital Management LLC now owns 325,548 shares of the health services provider’s stock worth $30,562,000 after purchasing an additional 20,482 shares in the last quarter. 91.42% of the stock is owned by hedge funds and other institutional investors.

About LHC Group

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

Featured Story: Penny Stocks

Get a free copy of the Zacks research report on LHC Group (LHCG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.